PRESS RELEASE

March 24, 2025

SNBL's Subsidiary, SNLD, Announces its Abstract Accepted at the Upcoming 77th American Academy of Neurology (AAN) 2025 Annual Meeting

TOKYO and KAGOSHIMA, Japan, March 24, 2025 – Shin Nippon Biomedical Laboratories, Ltd. (TSE Prime: 2395, hereinafter "SNBL") announces that SNLD, Ltd. (hereinafter "SNLD"), a consolidated subsidiary of SNBL specialized in development of novel therapies for the treatment of Parkinson's Disease (hereinafter "PD") utilizing SNBL's nasal drug delivery platform technology, will present a poster at the American Academy of Neurology (AAN) 2025 Annual Meeting. The meeting will be held from April 5 to 9, 2025, in San Diego, California, United States.

The presentation will highlight the results of Phase II proof-of-concept clinical study of TR-012001, a nasal levodopa. The study explored the safety and levodopa pharmacokinetics in Japanese PD patients (N=12). TR-012001 is being developed as a novel on-demand therapy candidate to treat OFF episodes in PD.

AAN 2025 Presentation Details:

Title: A Proof-of-Concept Study of TR-012001, a Nasal Levodopa, in Patients with Parkinson's Disease with OFF Episodes, Without Dopa Decarboxylase Inhibitor.
Session: Poster Session #11: Movement Disorders: Therapeutics in Study for Parkinson's Disease
Date/Time: Wednesday, April 9, 2025: from 8:00 a.m. to 9:00 a.m. (PDT).
Author: Masahiro Nomoto (Clinical Research Center and Neurology, Saiseikai Imabari Hospital, Imabari, Japan), et al.

About Parkinson's Disease (PD)
A progressive, neurodegenerative disorder first described in 1817 by Dr. James Parkinson in the UK, that affects predominantly the dopamine-producing neurons in a specific area of the brain called substantia nigra. It is known for four major symptoms: tremor (shaking in the arms and legs), rigidity (muscle and joint stiffness), bradykinesia (slowing down of movement), and postural instability (impaired balance and falls). In addition to these characteristic symptoms, non-motor symptoms such as psychiatric and cognitive problems are also gaining increasing attention in recent years. The estimated number of PD patients in Japan is about 250,000, while the number in the U.S. is about 1 million. The number of PD patients is expected to increase as the population ages.

About OFF episodes
OFF episodes are return of PD symptoms, resulted from shorten and unstable levodopa therapeutic effect after long-term levodopa treatment, and are not easy to manage, affecting patient's quality of life (QOL).

About Levodopa

Levodopa is a dopamine precursor capable of crossing the blood-brain barrier, converts to dopamine in the brain, and exhibits antiparkinsonian effects. It has been the primary treatment for PD for many decades.

About SNLD

SNLD is a wholly-owned subsidiary of SNBL established in October 2020 for the purpose of clinical development of novel intranasal therapies for PD and other central nervous system diseases. For more information, please visit SNLD website (Japanese only).

Inquiries
Shin Nippon Biomedical Laboratories, Ltd.
IR & Corporate Communications
Email: ir@snbl.com

#####